In light of the failure of BACE1 inhibitors to improve cognition in AD patients and the lack of effective adjunctive therapies for HAND, these SIRT1 and/or ADAM10 activators and inducers may present themselves as possible therapeutic alternatives [88,89,90,91,92]. The gene discussed is SIRT1; the disease is Alzheimer disease.